Compare Biocon Ltd with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs PIRAMAL ENTERPRISES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON PIRAMAL ENTERPRISES BIOCON /
PIRAMAL ENTERPRISES
 
P/E (TTM) x 25.4 15.5 163.7% View Chart
P/BV x 2.9 1.0 277.4% View Chart
Dividend Yield % 0.3 1.7 20.0%  

Financials

 BIOCON    PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    BIOCON
Mar-19
PIRAMAL ENTERPRISES
Mar-19
BIOCON /
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs7073,303 21.4%   
Low Rs5541,797 30.8%   
Sales per share (Unadj.) Rs91.9716.5 12.8%  
Earnings per share (Unadj.) Rs16.779.7 21.0%  
Cash flow per share (Unadj.) Rs24.2107.9 22.4%  
Dividends per share (Unadj.) Rs1.0028.00 3.6%  
Dividend yield (eoy) %0.21.1 14.4%  
Book value per share (Unadj.) Rs101.61,477.5 6.9%  
Shares outstanding (eoy) m600.00184.45 325.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x6.93.6 192.8%   
Avg P/E ratio x37.732.0 118.0%  
P/CF ratio (eoy) x26.123.6 110.4%  
Price / Book Value ratio x6.21.7 359.5%  
Dividend payout %6.035.1 17.0%   
Avg Mkt Cap Rs m378,330470,292 80.4%   
No. of employees `0006.17.8 78.4%   
Total wages/salary Rs m11,65322,504 51.8%   
Avg. sales/employee Rs Th8,994.316,899.4 53.2%   
Avg. wages/employee Rs Th1,900.72,877.7 66.0%   
Avg. net profit/employee Rs Th1,635.31,879.9 87.0%   
INCOME DATA
Net Sales Rs m55,144132,153 41.7%  
Other income Rs m1,4443,128 46.2%   
Total revenues Rs m56,588135,281 41.8%   
Gross profit Rs m15,88366,290 24.0%  
Depreciation Rs m4,4785,202 86.1%   
Interest Rs m70944,097 1.6%   
Profit before tax Rs m12,14020,119 60.3%   
Minority Interest Rs m93,194 0.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1238,611 24.7%   
Profit after tax Rs m10,02614,701 68.2%  
Gross profit margin %28.850.2 57.4%  
Effective tax rate %17.542.8 40.9%   
Net profit margin %18.211.1 163.4%  
BALANCE SHEET DATA
Current assets Rs m48,228122,742 39.3%   
Current liabilities Rs m30,376310,810 9.8%   
Net working cap to sales %32.4-142.3 -22.7%  
Current ratio x1.60.4 402.0%  
Inventory Days Days6823 296.0%  
Debtors Days Days8639 220.1%  
Net fixed assets Rs m64,130116,904 54.9%   
Share capital Rs m3,000369 813.2%   
"Free" reserves Rs m57,980272,161 21.3%   
Net worth Rs m60,980272,530 22.4%   
Long term debt Rs m15,766270,196 5.8%   
Total assets Rs m121,924856,261 14.2%  
Interest coverage x18.11.5 1,244.5%   
Debt to equity ratio x0.31.0 26.1%  
Sales to assets ratio x0.50.2 293.0%   
Return on assets %8.86.9 128.2%  
Return on equity %16.45.4 304.8%  
Return on capital %16.812.4 134.9%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50615,200 102.0%   
Fx outflow Rs m10,3994,889 212.7%   
Net fx Rs m5,10710,312 49.5%   
CASH FLOW
From Operations Rs m11,546-115,975 -10.0%  
From Investments Rs m-7,138-8,265 86.4%  
From Financial Activity Rs m-2,417107,525 -2.2%  
Net Cashflow Rs m2,103-16,650 -12.6%  

Share Holding

Indian Promoters % 40.4 52.9 76.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.0 210.0%  
FIIs % 10.7 26.6 40.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 16.5 120.6%  
Shareholders   109,995 93,274 117.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   TORRENT PHARMA  NATCO PHARMA  ELDER PHARMA  SANOFI INDIA  ALKEM LABORATORIES  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Scales 42,000 and Smallcaps Rebound: What Happens Next?(Podcast)

This week, the BSE Sensex crossed 42,000 level for the first time. While Nifty followed suit, hitting a record high of 12,377.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Jan 6, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 17, 2020 (Close)

TRACK BIOCON

BIOCON - GLENMARK PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS